D
Blueprint Medicines Corporation BPMC
$100.42 $0.61750.62% NASDAQ
Recommendation
Prev Close
$99.80
Volume
405,321
Avg Vol (90D)
1,027,944
Market Cap
$6.45B
Dividend & Yield
--
52-Week Range
$73.04 - $121.90
P/E (TTM)
--
EPS (TTM)
-$2.47
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Northern Trust Corp Has $53.06 Million Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC)
5/8/2025 - Ticker Report
Insider Sell: Christina Rossi Sells Shares of Blueprint Medicines Corp (BPMC)
5/7/2025 - GuruFocus
Bayesian Capital Management LP Makes New $1.62 Million Investment in Blueprint Medicines Co. (NASDAQ:BPMC)
5/7/2025 - MarketBeat
Blueprint Medicines (BPMC, $99.16) RSI Indicator left the overbought zone on May 06, 2025
5/7/2025 - Tickeron - Technical Analysis
Avidity Partners Management LP Sells 138,400 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)
5/6/2025 - MarketBeat
Algert Global LLC Raises Stake in Blueprint Medicines Co. (NASDAQ:BPMC)
5/6/2025 - MarketBeat
The Manufacturers Life Insurance Company Acquires 26,488 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)
5/6/2025 - MarketBeat
Alkeon Capital Management LLC Acquires 81,700 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)
5/5/2025 - MarketBeat
Bayesian Capital Management LP Makes New $1.62 Million Investment in Blueprint Medicines Co. (NASDAQ:BPMC)
5/5/2025 - Ticker Report
PDT Partners LLC Purchases Shares of 3,098 Blueprint Medicines Co. (NASDAQ:BPMC)
5/5/2025 - MarketBeat
There's Reason For Concern Over Blueprint Medicines Corporation's (NASDAQ:BPMC) Massive 28% Price Jump
5/4/2025 - Simply Wall St
Blueprint Medicines (NASDAQ:BPMC) Receives Buy Rating from HC Wainwright
5/4/2025 - MarketBeat
Ally Bridge Group NY LLC Has $4.88 Million Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)
5/4/2025 - MarketBeat
Avidity Partners Management LP Cuts Position in Blueprint Medicines Co. (NASDAQ:BPMC)
5/4/2025 - Ticker Report
Blueprint Medicines Stock Up Despite Lower-Than-Expected Q1 Earnings
5/2/2025 - Zacks Investment Research
BPMC: HC Wainwright & Co. Reiterates Buy Rating on Blueprint Medicines BPMC Stock News
5/2/2025 - GuruFocus
Blueprint Medicines (BPMC, $99.25) RSI Indicator left the overbought zone on May 01, 2025
5/2/2025 - Tickeron - Technical Analysis
Blueprint Medicines (BPMC, $99.25) price may drop as it broke higher Bollinger Band on May 01, 2025
5/2/2025 - Tickeron - Technical Analysis
Analysts' Opinions Are Mixed on These Healthcare Stocks: Teladoc (TDOC), Teleflex (TFX) and Blueprint Medicines (BPMC)
5/2/2025 - TipRanks Financial Blog
First Trust Advisors LP Sells 1,123 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)
5/2/2025 - Ticker Report
Blueprint Medicines Corp (BPMC) Q1 2025 Earnings Call Highlights: Strong AYVAKIT Revenue Growth ...
5/2/2025 - GuruFocus
Q1 2025 Blueprint Medicines Corp Earnings Call Transcript
5/2/2025 - GuruFocus
Blueprint Medicines Corporation (BPMC) Q1 2025 Earnings Call Transcript
5/1/2025 - Seeking Alpha: Transcripts
BPMC Makes Bullish Cross Above Critical Moving Average
5/1/2025 - Market News Video
Blueprint Medicines (BPMC) Reports Q1 Loss, Lags Revenue Estimates
5/1/2025 - Zacks Investment Research
Income Statement
Total Revenue (TTM)
$562.12M
EBITDA (TTM)
-$158.37M
EBIT (TTM)
-$174.31M
Net Income (TTM)
-$155.73M
Balance Sheet
Total Assets (Q)
$1.20B
Total Debt (Q)
$713.33M
Total Liabilities (Q)
$853.47M
Book Value Per Share (Q)
$5.30
Cash Flow
Cash from Operations (TTM)
-$145.55M
Cash from Investing (TTM)
-$59.55M
Cash from Financing (TTM)
$215.34M
Net Change in Cash (TTM)
$10.13M
Filings
Filing Date
Thursday, May 1, 2025
Period Date
Monday, March 31, 2025
Next Filing
Beginning of August (est)
Price History
Loading...
Beta
0.99
7-Day Total Return
13.44%
30-Day Total Return
10.64%
60-Day Total Return
-1.18%
90-Day Total Return
9.56%
Year to Date Total Return
15.11%
1-Year Total Return
-7.73%
2-Year Total Return
83.50%
3-Year Total Return
93.59%
5-Year Total Return
69.07%
52-week Low
Apr 09, 2025 - $73.04
52-week High
Jul 16, 2024 - $121.90
Valuation
Market Cap
$6.45B - Mid Cap
Enterprise Value
$6.26B
Price/Sales (TTM)
11.81
Price/Book (Q)
18.83
Dividends and Shares
Shares Outstanding
66.53M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.blueprintmedicines.com
Phone Number
(617) 374-7580
Address
45 Sidney Street
Cambridge, MA 02139
Country
United States
Year Founded
2008
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is... more
NASDAQ 05/08/2025 1:44PM Eastern Quotes delayed